A. Sahin, Secil Caban-Toktas, H. Tonbul, F. Yerlikaya, Y. Aktaş, Y. Capan
{"title":"紫杉醇和氟比洛芬共载PLGA纳米颗粒的研制:利用Plackett-Burman设计了解关键配方和工艺参数","authors":"A. Sahin, Secil Caban-Toktas, H. Tonbul, F. Yerlikaya, Y. Aktaş, Y. Capan","doi":"10.26650/istanbuljpharm.2019.19036","DOIUrl":null,"url":null,"abstract":"DOI : 10.26650/IstanbulJPharm.2019.19036 Nano drug co-delivery system is a popular strategy for combined application of two or more anticancer and/or synergistic drugs. Synergistic effects of nonsteroidal anti-inflammatory drugs and anti-cancer drugs in cancer treatment are shown in the literature. In this study, it was aimed to screen and understand critical formulation and process parameters inthe preparationflurbiprofen and paclitaxel co-loaded nanoparticles for developing an anti-cancer nano co-delivery system. With this aim, critical parameters were determined using Plackett–Burman experimental design (DoE). Flurbiprofen and paclitaxel drug loading amounts were considered as critical quality attributes to controleffective drug loading ratio. Furthermore, average particle size and zeta potential were also defined as critical quality attributes in order to optimize passive drug targeting and colloidal stability. Surfactant type was determined as the most significant factors for the average particle size and zeta potential. For flurbiprofen and paclitaxel drug loading into the nanoparticles, amounts of both flurbiprofen and paclitaxel were determined as critical factors. Consequently, paclitaxel and flurbiprofen were efficiently loaded into nanoparticles and the impact of the formulation variables were successfully screened by a DoE. By controlling the determined parameters, therapeutic efficacy of co-loaded drug nanoparticles could be maximized in further studies. You may cite this article as : Şahin A, Caban-Toktas S, Tonbul H, Yerlikaya F, Aktas Y, Capan Y (2019). Development of Paclitaxel and Flurbiprofen Co-Loaded PLGA Nanoparticles: Understanding Critical Formulation and Process Parameters Using Plackett–Burman Design. Istanbul J Pharm 10.26650/IstanbulJPharm.2019.19036.","PeriodicalId":14484,"journal":{"name":"İstanbul Journal of Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Development of Paclitaxel and Flurbiprofen Co-Loaded PLGA Nanoparticles: Understanding Critical Formulation and Process Parameters Using Plackett–Burman Design\",\"authors\":\"A. Sahin, Secil Caban-Toktas, H. Tonbul, F. Yerlikaya, Y. Aktaş, Y. Capan\",\"doi\":\"10.26650/istanbuljpharm.2019.19036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"DOI : 10.26650/IstanbulJPharm.2019.19036 Nano drug co-delivery system is a popular strategy for combined application of two or more anticancer and/or synergistic drugs. Synergistic effects of nonsteroidal anti-inflammatory drugs and anti-cancer drugs in cancer treatment are shown in the literature. In this study, it was aimed to screen and understand critical formulation and process parameters inthe preparationflurbiprofen and paclitaxel co-loaded nanoparticles for developing an anti-cancer nano co-delivery system. With this aim, critical parameters were determined using Plackett–Burman experimental design (DoE). Flurbiprofen and paclitaxel drug loading amounts were considered as critical quality attributes to controleffective drug loading ratio. Furthermore, average particle size and zeta potential were also defined as critical quality attributes in order to optimize passive drug targeting and colloidal stability. Surfactant type was determined as the most significant factors for the average particle size and zeta potential. For flurbiprofen and paclitaxel drug loading into the nanoparticles, amounts of both flurbiprofen and paclitaxel were determined as critical factors. Consequently, paclitaxel and flurbiprofen were efficiently loaded into nanoparticles and the impact of the formulation variables were successfully screened by a DoE. By controlling the determined parameters, therapeutic efficacy of co-loaded drug nanoparticles could be maximized in further studies. You may cite this article as : Şahin A, Caban-Toktas S, Tonbul H, Yerlikaya F, Aktas Y, Capan Y (2019). Development of Paclitaxel and Flurbiprofen Co-Loaded PLGA Nanoparticles: Understanding Critical Formulation and Process Parameters Using Plackett–Burman Design. Istanbul J Pharm 10.26650/IstanbulJPharm.2019.19036.\",\"PeriodicalId\":14484,\"journal\":{\"name\":\"İstanbul Journal of Pharmacy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"İstanbul Journal of Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26650/istanbuljpharm.2019.19036\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"İstanbul Journal of Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26650/istanbuljpharm.2019.19036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
纳米药物共递送系统是两种或多种抗癌和/或协同药物联合应用的流行策略。文献显示非甾体抗炎药和抗癌药物在癌症治疗中的协同作用。本研究旨在筛选和了解制备氟比洛芬和紫杉醇共载纳米颗粒的关键配方和工艺参数,以开发抗癌纳米共递送系统。为此,采用Plackett-Burman实验设计(DoE)确定了关键参数。氟比洛芬和紫杉醇载药量被认为是控制有效载药率的关键质量属性。此外,平均粒径和zeta电位也被定义为关键的质量属性,以优化被动药物靶向性和胶体稳定性。表面活性剂类型是影响平均粒径和zeta电位的最重要因素。对于氟比洛芬和紫杉醇类药物在纳米颗粒中的装载,氟比洛芬和紫杉醇的量被确定为关键因素。结果表明,紫杉醇和氟比洛芬被有效地装载到纳米颗粒中,并通过DoE成功地筛选了配方变量的影响。通过控制所确定的参数,可以在进一步的研究中最大限度地提高共载药物纳米颗粒的治疗效果。您可以将本文引用为:Şahin A, Caban-Toktas S, Tonbul H, Yerlikaya F, Aktas Y, Capan Y(2019)。紫杉醇和氟比洛芬共载PLGA纳米颗粒的研制:利用Plackett-Burman设计了解关键配方和工艺参数。IstanbulJPharm 10.26650/ istanbuljpharma .2019.19036。
Development of Paclitaxel and Flurbiprofen Co-Loaded PLGA Nanoparticles: Understanding Critical Formulation and Process Parameters Using Plackett–Burman Design
DOI : 10.26650/IstanbulJPharm.2019.19036 Nano drug co-delivery system is a popular strategy for combined application of two or more anticancer and/or synergistic drugs. Synergistic effects of nonsteroidal anti-inflammatory drugs and anti-cancer drugs in cancer treatment are shown in the literature. In this study, it was aimed to screen and understand critical formulation and process parameters inthe preparationflurbiprofen and paclitaxel co-loaded nanoparticles for developing an anti-cancer nano co-delivery system. With this aim, critical parameters were determined using Plackett–Burman experimental design (DoE). Flurbiprofen and paclitaxel drug loading amounts were considered as critical quality attributes to controleffective drug loading ratio. Furthermore, average particle size and zeta potential were also defined as critical quality attributes in order to optimize passive drug targeting and colloidal stability. Surfactant type was determined as the most significant factors for the average particle size and zeta potential. For flurbiprofen and paclitaxel drug loading into the nanoparticles, amounts of both flurbiprofen and paclitaxel were determined as critical factors. Consequently, paclitaxel and flurbiprofen were efficiently loaded into nanoparticles and the impact of the formulation variables were successfully screened by a DoE. By controlling the determined parameters, therapeutic efficacy of co-loaded drug nanoparticles could be maximized in further studies. You may cite this article as : Şahin A, Caban-Toktas S, Tonbul H, Yerlikaya F, Aktas Y, Capan Y (2019). Development of Paclitaxel and Flurbiprofen Co-Loaded PLGA Nanoparticles: Understanding Critical Formulation and Process Parameters Using Plackett–Burman Design. Istanbul J Pharm 10.26650/IstanbulJPharm.2019.19036.